Adicet Bio, Inc.
Adicet Bio, Inc.（ACET）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · ACET · 截至 2025年9月30日
股东结构概览
54
机构持有人数
▲ 6 vs Q2
$41.65M
机构持仓总市值
▲ $10.16M vs Q2
9.35M
总流通股
freeFloat 88.08%
51.40M
13F 申报持股数
▼ 201,071 vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
ACET 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
ORBIMED ADVISORS LLC pharmaceutical preparations | 11.45M | 12.57% | 12.57% | $9.27B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 8.22M | 9.03% | 9.03% | $6.66B | Nov 14, 2025 | — held |
RA CAPITAL MANAGEMENT, L.P. pharmaceutical preparations | 7.54M | 8.28% | 8.28% | $6.11B | Nov 14, 2025 | — held |
GOLDMAN SACHS GROUP INC pharmaceutical preparations | 3.75M | 4.12% | 4.12% | $3.04B | Nov 14, 2025 | ▼ 481 |
VANGUARD GROUP INC pharmaceutical preparations | 3.27M | 3.59% | 3.59% | $2.65B | Nov 7, 2025 | — held |
CARLYLE GROUP INC. pharmaceutical preparations | 2.95M | 3.24% | 3.24% | $2.39B | Nov 7, 2025 | — held |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 2.27M | 2.49% | 2.49% | $1.83B | Nov 13, 2025 | ▲ 190.9K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 1.83M | 2.01% | 2.01% | $1.48B | Nov 13, 2025 | ▲ 675.1K |
REGENERON PHARMACEUTICALS, INC. pharmaceutical preparations | 968.2K | 1.06% | 1.06% | $784.42M | Nov 7, 2025 | — held |
BRIDGEWAY CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 901.6K | 98.98% | 98.98% | $730.48M | Nov 14, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
16
增持
+2.10M 股7
新建仓
首次建仓10
减持
−1.73M 股0
清仓
完全退出净股数变化（前50家）
+367.8K
+2.10M / −1.73M
净新增持仓人
+13
新建 7 个 / 退出 0 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
ACET 内幕交易记录
数据来源：SEC Form 4
近期内部人员净买入。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
1
买入笔数
5
卖出笔数
0.20
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Apr 27, 2026 | J-Other | 250,000 | $0.00 | $25 | 1.40M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Apr 27, 2026 | J-Other | 250,000 | $0.00 | $25 | 932.6K | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Feb 20, 2026 | Purchase | 74,751 | $7.27 | $543.4K | 1.18M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Feb 19, 2026 | Purchase | 74,268 | $7.21 | $535.5K | 1.11M | Form 4 ↗ |
RA CAPITAL MANAGEMENT, L.P. 10 percent owner | Feb 18, 2026 | Purchase | 74,577 | $7.04 | $525.0K | 1.03M | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 7, 2026 | Sale | 29,319 | $6.53 | $191.5K | 34.9K | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 7, 2026 | Sale | 2,400 | $6.38 | $15.3K | 32.5K | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 8, 2026 | Sale | 32,523 | $6.29 | $204.6K | 0 | Form 4 ↗ |
ORBIMED ADVISORS LLC 10 percent owner | Apr 8, 2026 | Sale | 40,416 | $6.52 | $263.5K | 0 | Form 4 ↗ |
Harvey Brian Nicholas Chief Financial Officer | Mar 25, 2026 | Award | 43,361 | $6.81 | $295.3K | 43.4K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
Adicet Bio, Inc.（ACET）主要由机构投资者持有，机构持股比例约为 100.0%。公司内部人员持股约 11.92%，散户及公众持股约占剩余的 0.00%。
Adicet Bio, Inc. 最大机构股东为 ORBIMED ADVISORS LLC，截至 September 30, 2025 持有约 11.45 million 股，占总流通股的 12.57%。
目前共有 54 家机构持有 ACET 股票，合计持仓市值约 $41,645,212，数据来源为最新 SEC 13F 申报。
常见问题
ACET ownershipAdicet Bio, Inc.（ACET）主要由机构投资者持有，机构持股约 100.0%。最大股东为 ORBIMED ADVISORS LLC，持股比例 12.57%。内部人员持股约 11.92%。数据来源 SEC Form 13F，截至 September 30, 2025。